COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience

J Dermatolog Treat. 2022 Mar;33(2):1181-1182. doi: 10.1080/09546634.2020.1789041. Epub 2020 Jul 9.

Authors

Mohammad Shahidi-Dadras¹, Fahimeh Abdollahimajd¹, Laya Ohadi¹, Mohammadreza Tabary², Farnaz Araghi¹, Nikoo Mozafari^{1

3}, Parviz Toosi¹, Sahar Dadkhahfar¹

Affiliations

¹ Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
³ Department of Dermatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

PMID: 32594787
DOI: 10.1080/09546634.2020.1789041

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Humans
Immunologic Factors
Pemphigus* / drug therapy
Rituximab / therapeutic use
Treatment Outcome

Substances

Immunologic Factors
Rituximab